TY - JOUR
T1 - Clinical Phenotype of Pediatric and Adult Patients With Spinal Muscular Atrophy With Four SMN2 Copies: Are They Really All Stable?
AU - Ricci, Martina
AU - Cicala, Gianpaolo
AU - Capasso, Anna
AU - Coratti, Giorgia
AU - Fiori, Simona
AU - Cutrona, Costanza
AU - D'Amico, Adele
AU - Sansone, Valeria A.
AU - Bruno, Claudio
AU - Messina, Sonia
AU - Mongini, Tiziana
AU - Coccia, Michela
AU - Siciliano, Gabriele
AU - Siciliano, Giovanni
AU - Pegoraro, Elena
AU - Masson, Riccardo
AU - Filosto, Massimiliano
AU - Comi, Giacomo P.
AU - Corti, Stefania
AU - Corti, Serafino
AU - Ronchi, Dario
AU - Maggi, Lorenzo
AU - D'Angelo, Maria G.
AU - D'Angelo Bozzi, Michele Giovanni
AU - Vacchiano, Veria
AU - Ticci, Chiara
AU - Ruggiero, Lucia
AU - Verriello, Lorenzo
AU - Ricci, Federica S.
AU - Berardinelli, Angela L.
AU - Maioli, Maria Antonietta
AU - Garibaldi, Matteo
AU - Garibaldi, Ida Marina Elisabetta
AU - Nigro, Vincenzo
AU - Previtali, Stefano C.
AU - Pera, Maria Carmela
AU - Tizzano, Eduardo
AU - Pane, Marika
AU - Tiziano, Francesco Danilo
AU - Mercuri, Eugenio Maria
PY - 2023
Y1 - 2023
N2 - Objective: The aim of this study was to provide an overview of the clinical phenotypes associated with 4 SMN2 copies. Methods: Clinical phenotypes were analyzed in all the patients with 4 SMN2 copies as part of a nationwide effort including all the Italian pediatric and adult reference centers for spinal muscular atrophy (SMA). Results: The cohort includes 169 patients (102 men and 67 women) with confirmed 4 SMN2 copies (mean age at last follow-up = 36.9 ± 19 years). Six of the 169 patients were presymptomatic, 8 were classified as type II, 145 as type III (38 type IIIA and 107 type IIIB), and 8 as type IV. The remaining 2 patients were asymptomatic adults identified because of a familial case. The cross-sectional functional data showed a reduction of scores with increasing age. Over 35% of the type III and 25% of the type IV lost ambulation (mean age = 26.8 years ± 16.3 SD). The risk of loss of ambulation was significantly associated with SMA type (p < 0.0001), with patients with IIIB and IV less likely to lose ambulation compared to type IIIA. There was an overall gender effect with a smaller number of women and a lower risk for women to lose ambulation. This was significant in the adult (p = 0.009) but not in the pediatric cohort (p = 0.43). Interpretation: Our results expand the existing literature on natural history of 4 SMN2 copies confirming the variability of phenotypes in untreated patients, ranging from type II to type IV and an overall reduction of functional scores with increasing age. ANN NEUROL 2023;94:1126–1135.
AB - Objective: The aim of this study was to provide an overview of the clinical phenotypes associated with 4 SMN2 copies. Methods: Clinical phenotypes were analyzed in all the patients with 4 SMN2 copies as part of a nationwide effort including all the Italian pediatric and adult reference centers for spinal muscular atrophy (SMA). Results: The cohort includes 169 patients (102 men and 67 women) with confirmed 4 SMN2 copies (mean age at last follow-up = 36.9 ± 19 years). Six of the 169 patients were presymptomatic, 8 were classified as type II, 145 as type III (38 type IIIA and 107 type IIIB), and 8 as type IV. The remaining 2 patients were asymptomatic adults identified because of a familial case. The cross-sectional functional data showed a reduction of scores with increasing age. Over 35% of the type III and 25% of the type IV lost ambulation (mean age = 26.8 years ± 16.3 SD). The risk of loss of ambulation was significantly associated with SMA type (p < 0.0001), with patients with IIIB and IV less likely to lose ambulation compared to type IIIA. There was an overall gender effect with a smaller number of women and a lower risk for women to lose ambulation. This was significant in the adult (p = 0.009) but not in the pediatric cohort (p = 0.43). Interpretation: Our results expand the existing literature on natural history of 4 SMN2 copies confirming the variability of phenotypes in untreated patients, ranging from type II to type IV and an overall reduction of functional scores with increasing age. ANN NEUROL 2023;94:1126–1135.
KW - Spinal Muscular Atrophy
KW - Spinal Muscular Atrophy
UR - http://hdl.handle.net/10807/260277
U2 - 10.1002/ana.26788
DO - 10.1002/ana.26788
M3 - Article
SN - 0364-5134
VL - 94
SP - 1126
EP - 1135
JO - Annals of Neurology
JF - Annals of Neurology
ER -